David Martin PhD
Stock Analyst at Bloom Burton
(4.80)
# 531
Out of 5,055 analysts
241
Total ratings
54%
Success rate
19.9%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.88 | $9.36 | +112.40% | 7 | Oct 1, 2026 | |
| TSXV: CNVI Conavi Medical Corp. | Reiterated: Buy | $1.00 → $1.30 | $0.14 | +828.57% | 3 | Sep 29, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $19.00 → $23.00 | $17.98 | +27.92% | 4 | Sep 23, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $74 → $71 | $33.90 | +109.44% | 9 | Sep 21, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $36 → $37 | $24.77 | +49.37% | 14 | Aug 26, 2026 | |
| TSXV: RX BioSyent Inc. | Reiterated: Buy | $18.00 | $15.89 | +13.28% | 15 | Aug 24, 2026 | |
| AUPH Aurinia Pharmaceuticals | Upgraded: Buy | $15 → $21 | $16.61 | +26.43% | 35 | Aug 20, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Reiterated: Buy | $0.40 | $0.31 | +31.15% | 14 | Aug 14, 2026 | |
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $40.00 | $30.65 | +30.51% | 3 | Aug 13, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Reiterated: Buy | $12.00 | $4.10 | +192.68% | 51 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6.00 → $6.50 | $4.83 | +34.58% | 14 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12.00 | $10.61 | +13.10% | 29 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 | $1.85 | +170.27% | 4 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 | $3.25 | +53.85% | 12 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.55 → $4.00 | $0.44 | +809.09% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $12.37 | -27.24% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $18.38 | -24.52% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $6.92 | $2.55 | n/a | 9 | Sep 8, 2020 |
Eupraxia Pharmaceuticals Inc.
Oct 1, 2026
Reiterated: Buy
Price Target: $19.88
Current: $9.36
Upside: +112.40%
Conavi Medical Corp.
Sep 29, 2026
Reiterated: Buy
Price Target: $1.00 → $1.30
Current: $0.14
Upside: +828.57%
DRI Healthcare Trust
Sep 23, 2026
Reiterated: Buy
Price Target: $19.00 → $23.00
Current: $17.98
Upside: +27.92%
Xenon Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $74 → $71
Current: $33.90
Upside: +109.44%
Zymeworks
Aug 26, 2026
Reiterated: Buy
Price Target: $36 → $37
Current: $24.77
Upside: +49.37%
BioSyent Inc.
Aug 24, 2026
Reiterated: Buy
Price Target: $18.00
Current: $15.89
Upside: +13.28%
Aurinia Pharmaceuticals
Aug 20, 2026
Upgraded: Buy
Price Target: $15 → $21
Current: $16.61
Upside: +26.43%
Microbix Biosystems Inc.
Aug 14, 2026
Reiterated: Buy
Price Target: $0.40
Current: $0.31
Upside: +31.15%
Apotex Health Corp.
Aug 13, 2026
Reiterated: Buy
Price Target: $40.00
Current: $30.65
Upside: +30.51%
HLS Therapeutics Inc.
Aug 13, 2026
Reiterated: Buy
Price Target: $12.00
Current: $4.10
Upside: +192.68%
Aug 12, 2026
Reiterated: Buy
Price Target: $6.00 → $6.50
Current: $4.83
Upside: +34.58%
Aug 7, 2026
Reiterated: Buy
Price Target: $12.00
Current: $10.61
Upside: +13.10%
Aug 5, 2026
Reiterated: Buy
Price Target: $5.00
Current: $1.85
Upside: +170.27%
Jul 31, 2026
Reiterated: Buy
Price Target: $5.00
Current: $3.25
Upside: +53.85%
Dec 11, 2025
Reiterated: Buy
Price Target: $8.55 → $4.00
Current: $0.44
Upside: +809.09%
Nov 19, 2025
Reiterated: Buy
Price Target: $9
Current: $12.37
Upside: -27.24%
Oct 21, 2025
Reiterated: Buy
Price Target: $14
Current: $18.38
Upside: -24.52%
Sep 8, 2020
Upgraded: Buy
Price Target: $6.92
Current: $2.55
Upside: n/a